The Top 10 Pitfalls of Participating in the 340B Drug Pricing Program

Health Care

July 03, 2014
by Vicki Mueller, CPA

Bookmark and Share
Vicki Mueller Vicki Mueller, CPA
Director

View Profile
 
 
Given today’s declining reimbursement landscape, most health care organizations are engaging in additional cost-saving strategies. The federal 340B Drug Pricing Program is one such opportunity that is available to critical access hospitals (CAHs), disproportionate share hospitals (DSHs), and other eligible covered entities. 

Whether your organization already participates in the 340B program or is considering it, it’s important to understand the compliance risks and overall program challenges. This article lists the top pitfalls to avoid to ensure a well-run program.

Download the article below to read more.

Average Rating:

Length: 2 pages (PDF 60 kB)



Rate this Article
*  =  required fields
Your Rating*
Name*
E-mail Address*
Company